| Symbol | PEPG |
|---|---|
| Name | PEPGEN INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 321 HARRISON AVENUE,8TH FLOOR, BOSTON, Massachusetts, 02118, United States |
| Telephone | +1 781 797-0979 |
| Fax | — |
| — | |
| Website | https://www.pepgen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001835597 |
| Description | PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Additional info from NASDAQ: |
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Read morePepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
Read moreRA CAPITAL MANAGEMENT, L.P. 🟢 acquired 34.0K shares (1 derivative) of PepGen Inc. (PEPG) at $1.79 Transaction Date: Jun 18, 2026 | Filing ID: 000684
Read moreDirector Wyman Lisa 🟢 acquired 34.0K shares (1 derivative) of PepGen Inc. (PEPG) at $1.79 Transaction Date: Jun 18, 2026 | Filing ID: 000034
Read moreDirector Mayer Howard 🟢 acquired 34.0K shares (1 derivative) of PepGen Inc. (PEPG) at $1.79 Transaction Date: Jun 18, 2026 | Filing ID: 000032
Read moreDirector Finer Mitchell H. 🟢 acquired 34.0K shares (1 derivative) of PepGen Inc. (PEPG) at $1.79 Transaction Date: Jun 18, 2026 | Filing ID: 000031
Read moreDirector Dable Habib J 🟢 acquired 34.0K shares (1 derivative) of PepGen Inc. (PEPG) at $1.79 Transaction Date: Jun 18, 2026 | Filing ID: 000030
Read moreDirector HENSON HEIDI 🟢 acquired 34.0K shares (1 derivative) of PepGen Inc. (PEPG) at $1.79 Transaction Date: Jun 18, 2026 | Filing ID: 000029
Read moreDirector KEATING LAURIE 🟢 acquired 34.0K shares (1 derivative) of PepGen Inc. (PEPG) at $1.79 Transaction Date: Jun 18, 2026 | Filing ID: 000028
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07220603 | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy T… | Phase2 | Myotonic Dystrophy 1 | Recruiting | 2025-12-23 | 2029-01-01 | ClinicalTrials.gov |
| NCT06833931 | A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amen… | Phase2 | Duchenne Muscular Dystrophy (DMD) | Withdrawn | 2024-12-17 | 2025-05-28 | ClinicalTrials.gov |
| NCT06667453 | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | Phase2 | Myotonic Dystrophy 1 | Recruiting | 2024-12-10 | 2027-03-01 | ClinicalTrials.gov |
| NCT06079736 | A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable … | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2024-01-03 | 2025-08-28 | ClinicalTrials.gov |
| NCT06204809 | Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myoto… | Phase1 | Myotonic Dystrophy 1 | Completed | 2023-12-12 | 2025-10-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| IV infusion | Other | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| PGN-EDO51 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT06079736 |
| Placebo | Other | Phase PHASE1 | Myotonic Dystrophy 1 | COMPLETED | NCT06204809 |
| PGN-EDODM1 for infusion | Other | Phase PHASE1 | Myotonic Dystrophy 1 | COMPLETED | NCT06204809 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT07220603 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| IV infusion | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| PGN-EDODM1 | DRUG | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT07220603 |
| Placebo | OTHER | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| PGN-EDODM1 for infusion | DRUG | Phase PHASE1 | Myotonic Dystrophy 1 | COMPLETED | NCT06204809 |
| PGN-EDO51 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT06079736 |